Advances in the pharmacological management of cutaneous T-cell lymphoma

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785. doi: 10.1182/blood-2004-09-3502
   PubMed Web of Science ®Google Scholar
• Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703. doi: 10.1182/blood-2018-11-881268
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140(5):419–437. doi: 10.1182/blood.2021012057
   PubMed Web of Science ®Google Scholar
• Quaglino P, Scarisbrick J, Roccuzzo G, et al. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: an EORTC-CLTG/ISCL survey. J Eur Acad Dermatol Venereol. 2023;37(4):680–688. doi: 10.1111/jdv.18852.
   PubMed Web of Science ®Google Scholar
• Horna P, Wang SA, Wolniak KL, et al. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: international guidelines for assay characteristics. Cytometry B Clin Cytom. 2021;100(2):142–155. doi: 10.1002/cyto.b.21878
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Giordano S, Avallone G, et al. Sézary syndrome: different erythroderma morphological features with proposal for a clinical score system. Cells. 2022 [cited 2022 Jan 20];11(3):333. doi: 10.3390/cells11030333
   PubMed Web of Science ®Google Scholar
• Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023. Eur J Cancer. 2023;195:113343. doi: 10.1016/j.ejca.2023.113343
   PubMed Web of Science ®Google Scholar
• Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2017;28(10):2517–2525. doi: 10.1093/annonc/mdx352
   PubMed Web of Science ®Google Scholar
• Kaye FJ, Pa B Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321(26):1784–1790. doi: 10.1056/NEJM198912283212603
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181(2):350–357. doi: 10.1111/bjd.17258
   PubMed Web of Science ®Google Scholar
• Quaglino P, Prince HM, Cowan R, et al. Treatment of early-stage mycosis fungoides: results from the PROspective cutaneous lymphoma international prognostic index (PROCLIPI) study. Br J Dermatol. 2021;184(4):722–730. doi: 10.1111/bjd.19252
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Mastorino L, Gallo G, et al. Folliculotropic mycosis fungoides: current guidance and experience from clinical practice. Clin Cosmet Investig Dermatol. 2022 [cited 2022 Sep 13];15:1899–1907. doi: 10.2147/CCID.S273063
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Horwitz SM, Ansell S, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020. J Natl Compr Canc Netw. 2020;18(5):522–536. doi: 10.6004/jnccn.2020.0022
   PubMed Web of Science ®Google Scholar
• Zic JA. Extracorporeal photopheresis in the treatment of mycosis fungoides and Sézary syndrome. Dermatol Clin. 2015;33(4):765–776. doi: 10.1016/j.det.2015.05.011
   PubMed Web of Science ®Google Scholar
• Wehkamp U, Ardigò M, Papadavid E, et al. Chlormethine gel for patients with mycosis fungoides cutaneous T cell lymphoma: a review of efficacy and safety in clinical trial and real-world settings. Adv Ther. 2022;39(9):3979–4002. doi: 10.1007/s12325-022-02219-w
   PubMed Web of Science ®Google Scholar
• Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32. doi: 10.1001/2013.jamadermatol.541
   PubMed Web of Science ®Google Scholar
• Querfeld C, Kim YH, Guitart J, et al. Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study. J Am Acad Dermatol. 2021 Jul 30;87(1):S209–211. doi: 10.1016/j.jaad.2021.06.896
   PubMed Web of Science ®Google Scholar
• Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real-world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021 May;22(3):407–414. doi: 10.1007/s40257-021-00591-x
   PubMed Web of Science ®Google Scholar
• Geskin LJ, Kim EJ, Angello JT, et al. Evaluating the treatment patterns of chlormethine/mechlorethamine gel in patients with stage I-IIA mycosis fungoides: by-time reanalysis of a randomized controlled phase 2 study. Clin Lymphoma Myeloma Leuk. 2021;21(2):119–24. e4. doi: 10.1016/j.clml.2020.11.022
   PubMed Web of Science ®Google Scholar
• Querfeld C, Scarisbrick J, Assaf C, et al. Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine/mechlorethamine gel in patients with stage IA–IIA mycosis fungoides. Dermatology. 2022;238(2):347–357. doi: 10.1159/000516138
   PubMed Web of Science ®Google Scholar
• Phan K, Ramachandran V, Fassihi H, et al. Comparison of narrowband UV-B with psoralen–UV-A phototherapy for patients with early-stage mycosis fungoides. JAMA Dermatol. 2019;155(3):335–341. doi: 10.1001/jamadermatol.2018.5204
   PubMed Web of Science ®Google Scholar
• Grandi V, Baldo A, Berti E, et al. Italian expert-based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides: results of an e-Delphi consensus. Photodermatol Photoimmunol Photomed. 2021 Jul;37(4):334–342. doi: 10.1111/phpp.12658
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286–292. doi: 10.1016/j.jaad.2014.10.014
   PubMed Web of Science ®Google Scholar
• O’Malley JT, de Masson A, Lowry EL, et al. Radiotherapy eradicates malignant T cells and is associated with improved survival in early-stage mycosis fungoides. Clin Cancer Res. 2020;26(2):408–418. doi: 10.1158/1078-0432.CCR-18-4147
   PubMed Web of Science ®Google Scholar
• Elsayad K, Weishaupt C, Moustakis C, et al. Ultrahypofractionated low-dose total skin electron beam in advanced-stage mycosis fungoides and Sézary syndrome. Int J Radiat Oncol Biol Phys. 2023;117(1):164–170. doi: 10.1016/j.ijrobp.2023.02.052
   PubMed Web of Science ®Google Scholar
• Campbell BA, Ryan G, McCormack C, et al. Lack of durable remission with conventional-dose total skin electron therapy for the management of sezary syndrome and multiply relapsed mycosis fungoides. Cancers (Basel). 2019 [cited 2019 Nov 8];11(11):1758. doi: 10.3390/cancers11111758
   PubMed Web of Science ®Google Scholar
• Nawar T, Elsayad K, Müller EC, et al. Quality of life in patients with mycosis fungoides and Sézary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapy. J Am Acad Dermatol. 2022;86(4):889–891. doi: 10.1016/j.jaad.2021.03.025
   PubMed Web of Science ®Google Scholar
• Ortiz-Romero PL, Maroñmaroñas Jiménez L, Muniesa C, et al. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2022;9(6):e425–e433. doi: 10.1016/S2352-3026(22)00107-7
   PubMed Web of Science ®Google Scholar
• Rook AH, Gelfand JM, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452–1461. doi: 10.1182/blood-2015-02-630335
   PubMed Web of Science ®Google Scholar
• Besner Morin C, Roberge D, Turchin I, et al. Tazarotene 0.1% cream as monotherapy for early-stage cutaneous T-Cell lymphoma. J Cutan Med Surg. 2016;20(3):244–248. doi: 10.1177/1203475415626686
   PubMed Web of Science ®Google Scholar
• Severson KJ, Cumsky HJL, Brumfiel CM, et al. Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: a prospective, open-label study. J Am Acad Dermatol. 2021;85(4):969–971. doi: 10.1016/j.jaad.2021.01.053
   PubMed Web of Science ®Google Scholar
• Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81. doi: 10.1182/blood-2014-07-588236
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Fernandez-Diez J, et al. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. Hematology. 2015;20(9):538–542. doi: 10.1179/1607845415Y.0000000002
   PubMed Web of Science ®Google Scholar
• Gosmann J, Stadler R, Quint KD, et al. Use of pegylated interferon alpha-2a in cutaneous T-cell lymphoma: a retrospective case collection. Acta Derm Venereol. 2023 [cited 2023 Oct 30];103:adv10306. doi: 10.2340/actadv.v103.10306
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Fava P, Avallone G, et al. Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin. Br J Dermatol. 2022;187(6):1019–1021. doi: 10.1111/bjd.21772
   PubMed Web of Science ®Google Scholar
• Hamada T, Morita A, Suga H, et al. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: real-world experience from post-marketing surveillance. J Dermatol. 2022;49(2):253–262. doi: 10.1111/1346-8138.16201
   PubMed Web of Science ®Google Scholar
• Laggis CW, Lamb A, Secrest AM, et al. Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution. J Eur Acad Dermatol Venereol. 2021;35(1):e42–e45. doi: 10.1111/jdv.16790
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Patsatsi A, Sidiropoulou P, et al. Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study. J Eur Acad Dermatol Venereol. 2020;34(11):2534–2540. doi: 10.1111/jdv.16567
   PubMed Web of Science ®Google Scholar
• Elsayad K, Rolf D, Sunderkötter C, et al. Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma. J Dtsch Dermatol Ges. 2022;20(3):279–285. doi: 10.1111/ddg.14657
   Web of Science ®Google Scholar
• Blazejak C, Stranzenbach R, Gosman J, et al. Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment: real-life data from the German cutaneous lymphoma network. Dermatology. 2022;2021(3):498–506. doi: 10.1159/000517830
   Google Scholar
• Di Raimondo C, Vaccarini S, Nunzi A, et al. Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: a retrospective study. Dermatol Ther. 2022;35(6):e15482. doi: 10.1111/dth.15482
   PubMed Web of Science ®Google Scholar
• Falkenhain-López D, Puerta-Peña M, Fulgencio-Barbarin J, et al. Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas. Clin Exp Dermatol. 2022;47(9):1712–1715. doi: 10.1111/ced.15224
   PubMed Web of Science ®Google Scholar
• Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):6639–6647. doi: 10.1182/bloodadvances.2023011041.
   PubMed Web of Science ®Google Scholar
• Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204. doi: 10.1016/S1470-2045(18)30379-6
   PubMed Web of Science ®Google Scholar
• Porcu P, Hudgens S, Horwitz S, et al. Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(2):97–105. doi: 10.1016/j.clml.2020.09.003
   PubMed Web of Science ®Google Scholar
• Cowan RA, Scarisbrick JJ, Zinzani PL, et al. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2225–2238. doi: 10.1111/jdv.17523
   PubMed Web of Science ®Google Scholar
• Weiner D, Rastogi S, Lewis DJ, et al. Mogamulizumab multimodality therapy with systemic retinoids, interferon, or extracorporeal photopheresis for advanced cutaneous T-cell lymphoma. Dermatologic Therapy. 2023;2023:Article ID 7625926. doi: 10.1155/2023/7625926
   Web of Science ®Google Scholar
• Ninosu N, Melchers S, Kappenstein M, et al. Mogamulizumab combined with extracorporeal photopheresis as a novel therapy in erythrodermic cutaneous T-cell lymphoma. Cancers (Basel). 2024;16(1):141. doi: 10.3390/cancers16010141
   Web of Science ®Google Scholar
• Avallone G, Roccuzzo G, Pileri A, Agostinelli C, et al. Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: a systematic review. J Eur Acad Dermatol Venereol. Published online 2024 Jan 26. doi: 10.1111/jdv.19801
   Web of Science ®Google Scholar
• Roelens M, de Masson A, Andrillon A, et al. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome. Br J Dermatol. 2022;186(6):1010–1025. doi: 10.1111/bjd.21018
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566. doi: 10.1016/S0140-6736(17)31266-7
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Cavallo F, Avallone G, et al. Guttate psoriasis in a patient with mycosis fungoides in treatment with brentuximab vedotin: an unreported association. Dermatol Ther. 2022;35(4):e15309. doi: 10.1111/dth.15309
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098–5106. doi: 10.1182/bloodadvances.2021004710
   PubMed Web of Science ®Google Scholar
• Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis. Eur J Cancer. 2021;148:411–421. doi: 10.1016/j.ejca.2021.01.054
   PubMed Web of Science ®Google Scholar
• Jagadeesh D, Horwitz S, Bartlett NL, et al. Response to brentuximab vedotin by CD30 expression in non-hodgkin lymphoma. Oncology. 2022;27(10):864–873. doi: 10.1093/oncolo/oyac137
   Google Scholar
• Iqbal M, Reljic T, Ayala E, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2020;26(1):76–82. doi: 10.1016/j.bbmt.2019.08.019
   PubMed Web of Science ®Google Scholar
• Goyal A, O’Leary D, Foss F. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis. Bone Marrow Transplant. 2024;59(1):4151. doi: 10.1038/s41409-023-02122-0
   Web of Science ®Google Scholar
• de Masson A, Beylot-Barry M, Ram-Wolff C, et al. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023;401(10392):1941–1950. doi: 10.1016/S0140-6736(23)00329-X
   PubMed Web of Science ®Google Scholar
• Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160–1170. doi: 10.1016/S1470-2045(19)30320-1
   PubMed Web of Science ®Google Scholar
• Bagot M, Kim YH, Ortiz-Romero PL, et al. Lacutamab in patients with advanced sezary syndrome: results from an interim analysis of the tellomak phase 2 trial. Blood. 2022;140(Supplement 1):3760–3761. doi: 10.1182/blood-2022-160239
   Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study. J Clin Oncol. 2016;34(23):2698–2704. doi: 10.1200/JCO.2015.65.9789
   PubMed Web of Science ®Google Scholar
• Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20–28. doi: 10.1200/JCO.19.01056
   PubMed Web of Science ®Google Scholar
• Marchi E, Ma H, Montanari F, et al. The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). J Clin Oncol. 2020;38(15_suppl):8049–9. doi: 10.1200/JCO.2020.38.15_suppl.8049
   Web of Science ®Google Scholar
• Beygi S, Fernandez-Pol S, Duran G, et al. Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Adv. 2021;5(3):771–774. doi: 10.1182/bloodadvances.2020002371
   PubMed Web of Science ®Google Scholar
• Sekulic A, Liang WS, Tembe W, et al. Personalized treatment of Sézary syndrome by targeting a novel CTLA4: CD28 fusion. Mol Genet Genomic Med. 2015;3(2):130–136. doi: 10.1002/mgg3.121
   PubMed Web of Science ®Google Scholar
• Lai P, Wang Y. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials. Cancer Biol Med. 2021;18(1):34–51. doi: 10.20892/j.issn.2095-3941.2020.0216
   PubMed Web of Science ®Google Scholar
• Foss F, Advani R, Duvic M, et al. A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811–819. doi: 10.1111/bjh.13222
   PubMed Web of Science ®Google Scholar
• Stadler R, Scarisbrick JJ. Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: a neglected topic. Eur J Cancer. 2021;142:38–47. doi: 10.1016/j.ejca.2020.10.007
   PubMed Web of Science ®Google Scholar
• Emge DA, Bassett RL, Duvic M, et al. Methicillin-resistant staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. Arch Dermatol Res. 2020;312(4):283–288. doi: 10.1007/s00403-019-02015-7
   PubMed Web of Science ®Google Scholar
• Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019;134(13):1072–1083. doi: 10.1182/blood.2018888107
   PubMed Web of Science ®Google Scholar
• Dai J, Duvic M. Cutaneous T-cell lymphoma: current and emerging therapies. Oncology (Williston Park). 2023;37(2):55–62.
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Moirano G, Fava P, et al. Obesity and immune-checkpoint inhibitors in advanced melanoma: a meta-analysis of survival outcomes from clinical studies. Semin Cancer Biol. 2023;91:27–34. doi: 10.1016/j.semcancer.2023.02.010
   PubMed Web of Science ®Google Scholar
• Dobos G, Lazaridou I, de Masson A. Mycosis fungoides and Sézary syndrome: microenvironment and cancer progression. Cancers (Basel). 2023 [cited 2023 Jan 25];15(3):746. doi: 10.3390/cancers15030746
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Giordano S, Fava P, et al. Immune check point inhibitors in primary cutaneous T-cell lymphomas: biologic rationale, clinical results and future perspectives. Front Oncol. 2021 [cited 2021 Aug 16];11:733770. doi: 10.3389/fonc.2021.733770
   PubMed Web of Science ®Google Scholar
• Cetinözman F, Jansen PM, Vermeer MH, et al. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides. Arch Dermatol. 2012;148(12):1379–1385. doi: 10.1001/archdermatol.2012.2089
   PubMed Web of Science ®Google Scholar
• Phillips D, Matusiak M, Gutierrez BR, et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat Commun. 2021;12(1):6726. doi: 10.1038/s41467-021-26974-6
   PubMed Web of Science ®Google Scholar